The U.S. Food and Drug Administration has approved Baxter International Inc.’s new formulations of Clinimix (amino acids in dextrose) injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) injections.
“The introduction of Clinimix and Clinimix E formulations offers the highest protein in a multi-chamber bag in the U.S., allowing clinicians more flexibility in meeting their patients’ nutritional goals,” said Heather Knight, general manager of Baxter’s U.S. hospital products business. “Clinimix and Clinimix E with Higher Protein complement Baxter’s diverse portfolio of formulations that focus on helping improve care for critically ill patients.”
In addition to these new higher protein formulations intended for patients with moderate to high protein needs, Baxter will continue to provide existing formulations of Clinimix and Clinimix E for patients with lower protein needs. The approval of Clinimix and Clinimix E with Higher Protein follows the U.S. introduction of Clinolipid (20% Lipid Injectable Emulsion), the company’s proprietary olive oil-based lipid emulsion.
Deerfield-based Baxter provides products and services designed to be used in different health care environments, including in the ICU and the hospital, nursing homes, clinics and in homes.
To learn more, visit baxter.com.